USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - - for patients with non-st-segment elevation acs [unstable angina (ua)/non-st-elevation myocardial infarction (nstemi)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, clopidogrel tablets usp have been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (mi), or stroke as well as the rate of a combined endpoint of cardiovascular death, mi, stroke, or refractory ischemia. - for patients with st-elevation myocardial infarction (stemi), clopidogrel tablets usp have been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. the benefit for patients who undergo primary percutaneous coronary intervention is unknown. the optimal duration of clopidogrel tablet usp therapy in acs is unknown. for patients with a history of recent myocardial infarction (mi), recent stroke, or established peripheral arterial disease, clopidogrel tablets usp ha

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 40 mg

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride 5 mg

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 10 mg

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium tablets, usp are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihyper

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 40 mg

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - atorvastatin calcium trihydrate (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, atorvastatin calcium tablets can be started simultaneously with diet. in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: - reduce the risk of myocardial infarction - reduce the risk of stroke - reduce the risk for revascularization procedures and angina in adult  patients with type 2 diabetes, and without clinically evident coronary heart diseas

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - simvastatin 20 mg

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - cyclobenzaprine hydrochloride (unii: 0ve05jys2p) (cyclobenzaprine - unii:69o5wqq5ti) - cyclobenzaprine hydrochloride 5 mg - cyclobenzaprine hcl tablets usp are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. cyclobenzaprine hcl should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted.   cyclobenzaprine hcl has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. hypersensitivity to any component of this product. concomitant use of monoamine oxidase (mao) inhibitors or within 14 days after their discontinuation. h

USA - engelska - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - sertraline hydrochloride (unii: uti8907y6x) (sertraline - unii:quc7nx6wmb) - sertraline 25 mg